You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial

 

Online download statistics by month:

Online download statistics by month: May 2022 to October 2025

AbstractFullPdf
May 2022370379188
Jun 2022251256111
Jul 202216516759
Aug 202216716868
Sep 202214214937
Oct 202218118639
Nov 202215015120
Dec 202210210316
Jan 20239710022
Feb 2023949629
Mar 2023787914
Apr 2023585916
May 2023565615
Jun 202310310423
Jul 2023888820
Aug 2023656518
Sep 2023606014
Oct 2023727212
Nov 2023888827
Dec 2023555612
Jan 2024535417
Feb 2024383813
Mar 2024424227
Apr 2024404225
May 2024526045
Jun 2024394027
Jul 2024555718
Aug 2024545319
Sep 2024707016
Oct 2024797936
Nov 2024727329
Dec 2024666835
Jan 2025888855
Feb 2025474730
Mar 2025494919
Apr 2025696932
May 2025464628
Jun 2025323317
Jul 2025110
Oct 2025111
Total343534921249